Middle East & Africa Keytruda Market Size & Outlook
Global Market
Related Markets
MEA keytruda market highlights
- The MEA keytruda market generated a revenue of USD 1,483.9 million in 2025.
- The market is expected to grow at a CAGR of -8.1% from 2026 to 2033.
- In terms of segment, lung cancer was the largest revenue generating application in 2025.
- Breast Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2026 to 2033.
MEA data book summary
| Market revenue in 2025 | USD 1,483.9 million |
| Market revenue in 2033 | USD 824.3 million |
| Growth rate | -8.1% (CAGR from 2026 to 2033) |
| Largest segment | Lung cancer |
| Fastest growing segment | Breast Cancer |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma, Head and Neck Cancer, Gastric Cancer, Urothelial Cancer |
| Key market players worldwide | Merck & Co Inc, Bristol-Myers Squibb Co, Roche Holding AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Amgen Inc, Samsung Bioepis, Bio-Thera Solutions |
Other key industry trends
- In terms of revenue, MEA region accounted for 4.7% of the global keytruda market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,879.5 million by 2033.
The Middle East & Africa region is experiencing increased demand for Keytruda, driven by improving healthcare infrastructure and rising cancer prevalence.
Countries like Saudi Arabia are leading the market with government-driven investments in cancer care. However, limited healthcare accessibility, high treatment costs, and regulatory delays remain significant challenges.
No credit card required*
Publish Date: Dec 23, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Keytruda Market Scope
Keytruda Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| Samsung Bioepis | View profile | 501-1000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbioepis.com |
| Bio-Thera Solutions | View profile | 251-500 | Guangzhou, Guangdong, China, Asia | bio-thera.com/EN/ |
Middle East & Africa Keytruda Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Keytruda Market Outlook will help companies and investors design strategic landscapes.
Lung Cancer was the largest segment with a revenue share of 26.47% in 2025.
Horizon Databook has segmented the Middle East & Africa keytruda market based on lung cancer, breast cancer, melanoma, hodgkin lymphoma, head and neck cancer, gastric cancer, urothelial cancer covering the revenue growth of each sub-segment from 2021 to 2033.
The Middle East & Africa region is experiencing increased demand for Keytruda, driven by improving healthcare infrastructure and rising cancer prevalence.
Countries like Saudi Arabia are leading the market with government-driven investments in cancer care. However, limited healthcare accessibility, high treatment costs, and regulatory delays remain significant challenges.
- Middle East & Africa Keytruda Market Application Outlook (Revenue, USD Million , 2021-2033)
- Lung Cancer
- Breast Cancer
- Melanoma
- Hodgkin Lymphoma
- Head and Neck Cancer
- Gastric Cancer
- Urothelial Cancer
- Others
- Middle East & Africa Keytruda Market Payer Outlook (Revenue, USD Million , 2021-2033)
- Commerical/Private
- Public
- Middle East & Africa Keytruda Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Specialty Pharmacy
Reasons to subscribe to Keytruda Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Keytruda Market Outlook databook
- Our clientele includes a mix of Keytruda Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Keytruda Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Keytruda Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Middle East Africa Keytruda Market, 2021-2033 (US$M)
MEA keytruda market statistics, by application, 2021-2033 (US$M)
